"For the vast majority of Alzheimer's patients, taking these drugs is probably not a worthwhile risk," said Clive Ballard, the paper's lead author, of the Wolfson Centre for Age-Related DiseasesKing's College London. at
"Would I want to take a drug that slightly reduced my aggression but doubled my risk of dying? I'm not sure I would," Ballard said.
The research was published Friday in the medical journal, Lancet Neurology.
Courtesy Associated Press
No comments:
Post a Comment